The Selective Late Sodium Current Inhibitor Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation

Abstract

Selective late INa inhibition with eleclazine does not alter DFT50 or dominant frequency of ventricular fibrillation when administered alone or in combination with amiodarone. Accordingly, eleclazine would not be anticipated to affect the margin of defibrillation safety in patients with ICDs.

Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial

“…2–6 The mechanism of antiarrhythmics in obviating recurrent VF or rearrest during resuscitation is conceptually complicated by the known effect of some antiarrhythmic drugs to increase the defibrillation threshold, an effect that should reduce the probability of successful defibrillation. 7–9 Even so, it was demonstrated almost two decades ago that both amiodarone and lidocaine can improve survival to hospital admission when administered for recurrent or refractory VF. 10–11 Later, the Resuscitation Outcomes Consortium (ROC) conducted the Amiodarone-Lidocaine-Placebo Study (ALPS), a large randomized controlled trial of amiodarone, lidocaine or placebo for treatment of recurrent or refractory VF.…”